These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3829343)

  • 21. Electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class IA agents for refractory recurrent ventricular tachycardias or ventricular fibrillation.
    Kim SG; Felder SD; Waspe LE; Fisher JD
    Am J Cardiol; 1986 Sep; 58(6):485-90. PubMed ID: 3529910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
    Raviele A; Di Pede F; Delise P; Piccolo E
    G Ital Cardiol; 1984 Sep; 14(9):644-54. PubMed ID: 6510619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventricular fibrillation in six adults without overt heart disease.
    Lemery R; Brugada P; Della Bella P; Dugernier T; Wellens HJ
    J Am Coll Cardiol; 1989 Mar; 13(4):911-6. PubMed ID: 2926043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idiopathic ventricular fibrillation: is there a role for electrophysiologic-guided antiarrhythmic drug therapy?
    Ruskin JN
    J Cardiovasc Electrophysiol; 1999 Oct; 10(10):1313-5. PubMed ID: 10515553
    [No Abstract]   [Full Text] [Related]  

  • 26. Out-of-hospital cardiac arrest in patients with no overt heart disease: electrophysiologic observations and clinical outcome.
    Bhandari AK; Hong R; Au P; McKay CR; Rahimtoola SH
    Can J Cardiol; 1988 Mar; 4(2):80-4. PubMed ID: 3365601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between ease of inducibility of arrhythmia with electrophysiologic testing and response to antiarrhythmic therapy.
    Amann FW; Blatt CM; Podrid PJ; Lown B
    Am Heart J; 1986 Apr; 111(4):625-31. PubMed ID: 3953383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiarrhythmic and electrophysiologic actions of bethanidine sulfate in primary ventricular fibrillation or life-threatening ventricular tachycardia.
    Benditt DG; Benson DW; Dunnigan A; Kriett JM; Pritzker MR; Bacaner MB
    Am J Cardiol; 1984 May; 53(9):1268-74. PubMed ID: 6711426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiologic drug testing in patients with malignant ventricular arrhythmias: importance of stimulation at more than one ventricular site.
    Morady F; Hess D; Scheinman MM
    Am J Cardiol; 1982 Nov; 50(5):1055-60. PubMed ID: 7137032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of programmed ventricular stimulation in predicting sudden death and sustained ventricular tachycardia in survivors of acute myocardial infarction.
    Zoni-Berisso M; Molini D; Mela GS; Vecchio C
    Am J Cardiol; 1996 Apr; 77(9):673-80. PubMed ID: 8651115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ventricular tachyarrhythmia. Drug therapy and evaluation of success].
    Seipel L; Kühlkamp V
    Z Kardiol; 1993; 82 Suppl 5():155-61. PubMed ID: 8154157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias.
    Foster MT; Peters RW; Froman D; Shorofsky SR; Gold MR
    Am J Cardiol; 1996 Jul; 78(1):47-50. PubMed ID: 8712117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative electrophysiologic findings between responders and nonresponders to class III antiarrhythmic drugs among patients with ventricular tachyarrhythmia.
    Naitoh N; Washizuka T; Takahashi K; Miyajima T; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):307-19. PubMed ID: 9711182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Out-of-hospital cardiac arrest: electrophysiologic observations and selection of long-term antiarrhythmic therapy.
    Ruskin JN; DiMarco JP; Garan H
    N Engl J Med; 1980 Sep; 303(11):607-13. PubMed ID: 6772952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased incidence of antiarrhythmic drug efficacy at electrophysiologic study associated with the use of a third extrastimulus.
    Swerdlow CD; Blum J; Winkle RA; Griffin JC; Ross DL; Mason JW
    Am Heart J; 1982 Nov; 104(5 Pt 1):1004-11. PubMed ID: 7136990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ventricular fibrillation in chronic heart disease].
    Pleskot M; Parízek P; Hodac M; Haman L; Stásek J; Cervinka P; Tauchman M
    Vnitr Lek; 2000 Feb; 46(2):80-6. PubMed ID: 11048528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Continuous ventricular tachyarrhythmia in patients without detectable organic heart disease: clinical and electrophysiologic findings].
    Schöls W; Brachmann J; Schmitt C; Waldecker B; Kübler W
    Z Kardiol; 1989 Dec; 78(12):790-6. PubMed ID: 2623922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study.
    Klein LS; Fineberg N; Heger JJ; Miles WM; Kammerling JM; Chang MS; Zipes DP; Prystowsky EN
    Am J Cardiol; 1988 May; 61(13):1024-30. PubMed ID: 3364357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.